0A8D.LSE Q/C Technologies, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0A8D.LSE undervalued?
Graham numberThe Graham number of Q/C Technologies, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Q/C Technologies, Inc. fundamental analysis
No fundamental analysis for Q/C Technologies, Inc. yet.
Q/C Technologies, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog …
Full company profileFinancial statements of Q/C Technologies, Inc. are not available yet.
Q/C Technologies, Inc. dividends
Q/C Technologies, Inc. has not paid dividends in the last 1 fiscal years.
Last stock split: 0.01:1 on Sep 2, 2025.
Who owns Q/C Technologies, Inc.
- Insiders 7.53%
- Institutions 9.03%
- Public & others 83.44%
- Free float 7.90M
Q/C Technologies, Inc. company profile
- Company name
- Q/C Technologies, Inc.
- Ticker
- 0A8D.LSE
- Exchange
- London Exchange
- Sector
- Technology
- Industry
- Computer Hardware
- Employees
- 3
- Fiscal year end
- December
- Address
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 856 848 8698
- Website
- qctechnologies.com
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Q/C Technologies, Inc. management
5- Mr. Joshua N. SilvermanExecutive Chairman of the Board · born 1970
- Mr. Ian Thomas Rhodes CPAChief Financial Officer · born 1973
- Dr. Mitchell Glass M.D.Chief Medical Officer & Director · born 1952
- Mr. Yossef EhrlichmanChief Technology Officer · born 1977
- Robert SchatzInvestor Relations Officer